$BTX breakout $3.80 AMEX Website https://encr
Post# of 41
Posted On: 09/25/2016 7:30:06 PM
$BTX breakout $3.80
AMEX
Website
Shares Outstanding 103.39M
Float 62.78M
% Held by Insiders 46.22%
% Held by Institutions 14.90%
Shares Short 4.73M
Short Ratio 29.68
Short % of Float 7.48%
Shares Short (prior month) 4.99M
Headlines
and Filings
BioTime, Inc., a biotechnology company, focuses on developing and commercializing novel therapies based on HyStem cell delivery and pluripotent stem cell technology platforms. The company focuses on regenerative medicine, which refers to therapies based on stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It is developing Renevia that is in pivotal clinical trial for HIV related facial lipoatrophy; AST-VAC1, a cancer immunotherapy that is in Phase II clinical trials for the treatment of acute myeloid leukemia; OpRegen, which is in Phase I/IIa clinical trial to treat the dry form of age-related macular degeneration; and AST-OPC1 that is in Phase I/II clinical trials for spinal cord injuries. The company also develops Premvia, a HyStem hydrogel formulation of cross-linked thiol-modified hyaluronan and thiol-modified gelatin to manage wounds; AST-VAC2 for non-small cell lung cancer; bone grafting products to treat orthopedic disorders; treatments for cardiovascular and related ischemic disorders; and liquid biopsy tests for diagnosis of cancer, as well as personal mobile health software products. In addition, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants, and GeneAnalytics, a novel gene set analysis tool. Further, the company develops and markets HepatoPac and HepatoMune assay kits for drug-development and safety-testing; stem cell research products; and Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.
AMEX
Website
Shares Outstanding 103.39M
Float 62.78M
% Held by Insiders 46.22%
% Held by Institutions 14.90%
Shares Short 4.73M
Short Ratio 29.68
Short % of Float 7.48%
Shares Short (prior month) 4.99M
Headlines
and Filings
BioTime, Inc., a biotechnology company, focuses on developing and commercializing novel therapies based on HyStem cell delivery and pluripotent stem cell technology platforms. The company focuses on regenerative medicine, which refers to therapies based on stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It is developing Renevia that is in pivotal clinical trial for HIV related facial lipoatrophy; AST-VAC1, a cancer immunotherapy that is in Phase II clinical trials for the treatment of acute myeloid leukemia; OpRegen, which is in Phase I/IIa clinical trial to treat the dry form of age-related macular degeneration; and AST-OPC1 that is in Phase I/II clinical trials for spinal cord injuries. The company also develops Premvia, a HyStem hydrogel formulation of cross-linked thiol-modified hyaluronan and thiol-modified gelatin to manage wounds; AST-VAC2 for non-small cell lung cancer; bone grafting products to treat orthopedic disorders; treatments for cardiovascular and related ischemic disorders; and liquid biopsy tests for diagnosis of cancer, as well as personal mobile health software products. In addition, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants, and GeneAnalytics, a novel gene set analysis tool. Further, the company develops and markets HepatoPac and HepatoMune assay kits for drug-development and safety-testing; stem cell research products; and Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.
(0)
(0)Lineage Cell Therapeutics, Inc. (LCTX) Stock Research Links
Scroll down for more posts ▼